lipid or blood pressure levels with appropriate medications). 3 Reducing increased lipid levels is important for the prevention of CVD events. 4 Statins (HMG-CoA reductase inhibitors) are currently the main class of lipid-lowering drugs and their use reduces the risk of CVD- associated morbidity and mortality. 2 Use of statins: online tool KCE Report 324 Dyslipidaemia is a trouble of function and/or concentration of plasmatic lipids. It includes a number of lipid metabolism troubles that may (...) : Cardiovascular Diseases; Decision Making, Computer-Assisted; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Primary prevention NLM Classification: WG 120 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2019/10.273/71 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications. How to refer to this document? De Meester C, Rondia K, Goorden T, Janssens S, Steyaert P, De Laet, C, Albertijn M, Kohn L

Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health U.S. National Library (...) Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Am J Cardiol Actions , 125 (2), 198-204 2020 Jan 15 Meta-analysis Comparing Combined Use of Eicosapentaenoic Acid and Statin to Statin Alone , , , , , , , , , , Affiliations Expand Affiliations 1 Department of Internal Medicine, University of Nevada Reno School of Medicine, Reno, Nevada. Electronic address: raj20490@gmail.com. 2 Department of Critical Care Medicine, St

Recommendations for (Discontinuation of) Statin Treatment in Older Adults: Review of Guidelines As a person's age increases and his/her health status declines, new challenges arise that may lead physicians to consider deprescribing statins. We aimed to provide insight into recommendations available in international cardiovascular disease prevention guidelines regarding discontinuation of statin treatment applicable to older adults.We systematically searched PubMed, EMBASE, EMCARE (...) , and the websites of guideline development organizations and online guideline repositories for cardiovascular disease prevention guidelines aimed at the general population. We selected all guidelines with recommendations (instructions and suggestions) on discontinuation of statin treatment applicable to older adults, published between January 2009 and April 2019. In addition, we performed a synthesis of information from all other recommendations for older adults regarding statin treatment. Methodological

Diagnosis of osteoporosis in statin-treated patients is dose-dependent Whether HMG-CoA-reductase inhibition, the main mechanism of statins, plays a role in the pathogenesis of osteoporosis, is not entirely known so far. Consequently, this study was set out to investigate the relationship of different kinds and dosages of statins with osteoporosis, hypothesising that the inhibition of the synthesis of cholesterol could influence sex-hormones and therefore the diagnosis of osteoporosis.Medical (...) claims data of all Austrians from 2006 to 2007 was used to identify all patients treated with statins to compute their daily defined dose averages of six different types of statins. We applied multiple logistic regression to analyse the dose-dependent risks of being diagnosed with osteoporosis for each statin individually.In the general study population, statin treatment was associated with an overrepresentation of diagnosed osteoporosis compared with controls (OR: 3.62, 95% CI 3.55 to 3.69, p<0.01

Add a fibrate to a statin? Add a fibrate to a statin? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Add a fibrate to a statin? View/ Open Date 2010-10 Format Metadata Abstract Do not routinely add a fibrate to a statin for patients with type 2 diabetes who are at high risk for cardiovascular events. Stength

Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study. To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting.Propensity matched cohort study.Population based cohort in Korea.29 771 adults with metabolic syndrome (≥40 years) receiving statin treatment. 2156 participants receiving combined treatment (statin plus fenofibrate (...) ) were weighted based on propensity score in a 1:5 ratio with 8549 participants using statin only treatment.Primary outcome was composite cardiovascular events including incident coronary heart disease, ischaemic stroke, and death from cardiovascular causes.The incidence rate per 1000 person years of composite cardiovascular events was 17.7 (95% confidence interval 14.4 to 21.8) in the combined treatment group and 22.0 (20.1 to 24.1) in the statin group. The risk of composite cardiovascular events

Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Whether statin type influences hepatocellular carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.To assess the relationship between lipophilic or hydrophilic statin use and HCC incidence and mortality in a nationwide population with viral hepatitis.Prospective propensity score (PS)-matched (...) cohort.Swedish registers, 2005 to 2013.A PS-matched cohort of 16 668 adults (8334 who initiated statin use [6554 lipophilic and 1780 hydrophilic] and 8334 nonusers) among 63 279 eligible adults.Time to incident HCC, ascertained from validated registers. Statin use was defined from filled prescriptions as 30 or more cumulative defined daily doses (cDDDs).Compared with matched nonusers, 10-year HCC risk was significantly lower among lipophilic statin users (8.1% vs. 3.3%; absolute risk difference [RD], -4.8

Statins versus placebo for people with chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is a common, preventable, and treatable respiratory disease. COPD exacerbations are associated with worse quality of life, increased hospitalisations, and increased mortality. Currently available pharmacological interventions have variable impact on exacerbation frequency. The anti-inflammatory effects of statins may lead to decreased pulmonary and systemic inflammation (...) , resulting in fewer exacerbations of COPD. Several observational studies have shown potential benefits of statins for patients with COPD.This review aims to evaluate available evidence on benefits and harms associated with statin therapy compared with placebo as adjunct therapy for patients with COPD. Primary objectives include the following.• To determine whether statins reduce mortality rates in COPD.• To determine whether statins reduce exacerbation frequency, improve quality of life, or improve lung

Statin therapy increases lipoprotein(a) levels Lipoprotein(a) [Lp(a)] is elevated in 20-30% of people. This study aimed to assess the effect of statins on Lp(a) levels.This subject-level meta-analysis includes 5256 patients (1371 on placebo and 3885 on statin) from six randomized trials, three statin-vs.-placebo trials, and three statin-vs.-statin trials, with pre- and on-treatment (4-104 weeks) Lp(a) levels. Statins included atorvastatin 10 mg/day and 80 mg/day, pravastatin 40 mg/day (...) , rosuvastatin 40 mg/day, and pitavastatin 2 mg/day. Lipoprotein(a) levels were measured with the same validated assay. The primary analysis of Lp(a) is based on the log-transformed data. In the statin-vs.-placebo pooled analysis, the ratio of geometric means [95% confidence interval (CI)] for statin to placebo is 1.11 (1.07-1.14) (P < 0.0001), with ratio >1 indicating a higher increase in Lp(a) from baseline in statin vs. placebo. The mean percent change from baseline ranged from 8.5% to 19.6% in the statin

Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial To evaluate the lipid-lowering efficacy and safety of evolocumab combined with background atorvastatin in patients with type 2 diabetes mellitus (T2DM) and hyperlipidaemia or mixed dyslipidaemia.BERSON was a double-blind, 12-week, phase 3 study (NCT02662569) conducted in 10 countries. Patients ≥18 to ≤80 years with type T2DM received atorvastatin (...) -treated patients, and there were no clinically meaningful differences in changes over time in glycaemic variables (fasting serum glucose and HbA1c) between the two groups.In patients with T2DM and hyperlipidaemia or mixed dyslipidaemia on statin, evolocumab significantly reduced LDL-C and other atherogenic lipids, was well tolerated, and had no notable impact on glycaemic measures.© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Add a fibrate to a statin? Add a fibrate to a statin? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Add a fibrate to a statin? View/ Open Date 2010-10 Format Metadata Abstract Do not routinely add a fibrate to a statin for patients with type 2 diabetes who are at high risk for cardiovascular events. Stength

Statins do not increase risk of polyneuropathy: A case-control study and literature review To investigate whether there is an association between cholesterol-lowering medication use, specifically statins, and chronic polyneuropathy.A literature study was carried out to assess the current state of evidence on the association between chronic polyneuropathy and cholesterol-lowering medication use. We also conducted a prospective case-control study to compare exposure to cholesterol-lowering (...) . There was insufficient evidence that statin use is a risk factor for polyneuropathy. Our prospective case-control study included 333 patients with cryptogenic axonal polyneuropathy and 283 controls. Patients with polyneuropathy were less likely to have been exposed to statins than controls (OR 0.56, 95% confidence interval 0.34-0.95, p = 0.03). The odds of polyneuropathy decreased as exposure duration to statins increased. Cholesterol-lowering medication consisted almost exclusively of statins; therefore we only

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.In this meta-analysis, randomised trials (...) of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment duration of at least 2 years. We analysed individual participant data from 22 trials (n=134 537) and detailed summary data from one trial (n=12 705) of statin therapy versus control, plus individual participant data from five trials of more intensive versus less intensive statin therapy (n=39 612). We subdivided participants into six age groups (55 years or younger, 56-60 years, 61-65 years, 66

A, Taylor HL, Blackburn H, et al. Coronary Heart Disease among Minnesota Business and Professional Men Followed Fifteen Years. Circulation 28:381-95 (Sept 1963) 9. Tobert JA. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov. 2003;2(7):517-26. 10. Peter Landers. How one scientist intrigued by molds found first statin. Wall Street Journal. January 9, 2006. 11. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced (...) in August 1987. Although the main mechanism of statins to inhibit HMG-CoA reductase was understood, it was not until the work of Drs. Brown and Goldstein in the 1970’s that allowed us to fully comprehend how this class of medication lowers cholesterol. Working with tissue samples from people afflicted with familial hypercholesterolemia, Brown and Goldstein elucidated the cell-surface LDL receptor and demonstrated that inhibition of HMG-CoA reductase stimulates the upregulation of hepatic LDL receptors

HISTORICAL AND CURRENT STATIN USE IN BELGIUM 3.1 Introduction Statins (also known as HMG-CoA reductase inhibitors) are a class of lipid- lowering medications. Statins proved to reduce the relative risk for cardiovascular disease (CVD), CVD events and mortality similarly in all individuals, but the absolute risk reduction is much greater in those who are at high risk of CVD events. Statins are used both in the primary and secondary prevention of CVD. Clinical practice guidelines generally recommend (...) the full responsibility of the KCE. Publication date: 15 January 2019 Domain: Health Technology Assessment (HTA) MeSH: Hydroxymethylglutaryl-CoA Reductase Inhibitors; Cardiovascular Diseases; Primary prevention; Costs and Cost Analysis. NLM Classification: WG 120 Language: English Format: Adobe® PDF™ (A4) Legal depot: D/2019/10.273/07 ISSN: 2466-6459 Copyright: KCE reports are published under a “by/nc/nd” Creative Commons Licence http://kce.fgov.be/content/about-copyrights-for-kce-publications. How

of these events is a priority. Overall, in patients for whom statin treatment is recommended by current guidelines, the benefits greatly outweigh the risks. The development and use of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) class of drugs, which, according to the prescribing information, reduce low-density lipoprotein cholesterol (LDL-C) on average by 55% to 60% at the maximal doses of the most potent statins, has had a major impact in reducing the incidence (...) metabolites, which is equivalent to taking a larger dose, and thereby increases the risk of myopathy/rhabdomyolysis. The most important pharmacokinetic difference among the statins is that only lovastatin, simvastatin, and atorvastatin are cytochrome P450 3A4 (CYP3A4) substrates and consequently are vulnerable to drug interactions with CYP3A4 inhibitors, some of which are commonly used. Because of the high first-pass metabolism of lovastatin and simvastatin, the effects of CYP3A4 inhibitors

Finding the Balance Between Benefits and Harms When Using Statins for Primary Prevention of Cardiovascular Disease: A Modeling Study. Many guidelines use expected risk for cardiovascular disease (CVD) during the next 10 years as a basis for recommendations on use of statins for primary prevention of CVD. However, how harms were considered and weighed against benefits is often unclear.To identify the expected risk above which statins provide net benefit.Quantitative benefit-harm balance modeling (...) study.Network meta-analysis of primary prevention trials, a preference survey, and selected observational studies.Persons aged 40 to 75 years with no history of CVD.10 years.Clinicians and guideline developers.Low- or moderate-dose statin versus no statin.The 10-year risk for CVD at which statins provide at least a 60% probability of net benefit, with baseline risk, frequencies of and preferences for statin benefits and harms, and competing risk for non-CVD death taken into account.Younger men had net

Usefulness of Low-Dose Statin Plus Ezetimibe and/or Nutraceuticals in Patients With Coronary Artery Disease Intolerant to High-Dose Statin Treatment High-dose statin (HDS) therapy is recommended to reduce low-density lipoprotein cholesterol (LDL-C); however, some patients are unable to tolerate the associated side effects. Nutraceuticals have shown efficacy in lowering LDL-C. The aim of this study was to evaluate whether the combination of low-dose statin (LDS) plus ezetimibe (EZE) or LDS plus

Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials. Many effects of statins on non-cardiovascular disease (non-CVD) outcomes have been reported.To evaluate the quantity, validity, and credibility of evidence regarding associations between statins and non-CVD outcomes and the effects of statins on these outcomes.MEDLINE and EMBASE (English terms only, inception to 28 May 2018).Meta-analyses (published (...) in English) of observational studies and of randomized controlled trials (RCTs) that examined non-CVD outcomes of statin intake.Two investigators extracted data from meta-analyses and individual studies. Credibility assessments based on summary effect sizes from a random-effects model, between-study heterogeneity, 95% prediction interval, small-study effect, excess significance, and credibility ceilings were devised to classify evidence.This review explored 278 unique non-CVD outcomes from 112 meta

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. Elevated lipoprotein(a) is a genetic risk factor for cardiovascular disease in general population studies. However, its contribution to risk for cardiovascular events in patients with established cardiovascular disease or on statin therapy is uncertain.Patient-level data from seven randomised, placebo-controlled, statin outcomes trials (...) (a) measurements (mean age 62 years [SD 8]; 8064 [28%] women; 5751 events during 95 576 person-years at risk). Initiation of statin therapy reduced LDL cholesterol (mean change -39% [95% CI -43 to -35]) without a significant change in lipoprotein(a). Associations of baseline and on-statin treatment lipoprotein(a) with cardiovascular disease risk were approximately linear, with increased risk at lipoprotein(a) values of 30 mg/dL or greater for baseline lipoprotein(a) and 50 mg/dL or greater for on-statin